Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine 2014/2015 Influsplit Tetra (Fluarix Tetra) (GSK2321138A) When Co-administered With Pneumovax 23 in Adults 50 Years of Age and Older

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine 2014/2015 Influsplit Tetra (Fluarix Tetra) (GSK2321138A) When Co-administered With Pneumovax 23 in Adults 50 Years of Age and Older

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs GSK 2321138A (Primary) ; Pneumococcal vaccine conjugate PPV 23
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms FLU D-QIV-010 PRI
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Oct 2017 Primary endpoint (Anti-pneumococcal antibody concentrations against 6 pneumococcal serotypes (1, 3, 4, 7F, 14 and 19A) post-vaccination with PPV23 (23-valent pneumococcal polysaccharide vaccine)) has been met as per results published in the Vaccine
    • 05 Oct 2017 Primary endpoint (Humoral immune response to each strain. HI antibody titres against each influenza virus strain post-vaccination with D-QIV [GSK Biologicals quadrivalent influenza vaccine (inactivated, split virion)]) has been met as per results published in the Vaccine.
    • 05 Oct 2017 Results published in the Vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top